Cas No. 59107-51-6, 1-Amino-8-chloronaphthalenewith

With its selective inhibition of mutant KRAS G12C proteins, Adagrasib shows tremendous potential to revolutionize cancer treatment. This cutting-edge drug delivers remarkable efficacy and tolerability, offering hope to patients with limited treatment options. By adding Adagrasib to your pharmaceutical portfolio, you can contribute to the fight against KRAS G12C mutated cancers and make a meaningful impact on patients' lives.